The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 11 of the 29 sources its claims cite were checked for support.
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Open accessAbstract
We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 7 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“and additionally showed that modulation of the gut microbiome of germ-free mice via FMT from patients could alter anti-tumor immunity and response to ICI therapy in gnotobiotic mice11–13.”
§ Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis > Abstract
What the sources say
- Supportedcites [11] Gopalakrishnan, V. et al. Science 359, 97–103 (2018). source
The Results (Fig. 4G–I passage) state that to test a causal link the authors performed FMT into germ-free recipient mice, and that R-FMT mice had significantly reduced tumor growth (p=0.04) and improved responses to anti-PD-L1 therapy versus NR-FMT. The following passage (Fig. 4J–K, fig. S26) reports altered anti-tumor immunity in these gnotobiotic mice — higher intratumoral CD8+ T cell density, more CD45+/CD8+ cells in gut, up-regulated PD-L1, enriched innate effectors, fewer suppressive myeloid cells. The abstract likewise notes 'enhanced systemic and anti-tumor immunity ... in germ-free mice receiving fecal transplants from responding patients.' (LLM, conf=0.90)
- Supportedcites [12] Matson, V. et al. Science 359, 104–108 (2018). source
The Abstract (p. 1) states that 'Reconstitution of germ-free mice with fecal material from responding patients could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti-PD-L1 therapy,' covering both limbs of the claim (anti-tumor immunity and response to checkpoint blockade). The Results sections corroborate this: fecal transfer from three R and three NR patients into GF cohorts segregated tumor growth rate to mirror the donor's clinical outcome (p. 4-5), with increased SIY-specific CD8+ T cells and IFN-g ELISPOT frequencies and anti-PD-L1 efficacy in R-derived but not NR-derived mice (p. 6). The discussion also notes agreement with the two companion studies because 'fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (p. 8). (LLM, conf=0.93)
- Not checked yetcites [13] Routy, B. et al. Science 359, 91–97 (2018). source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“consistent with findings from reports of autoimmune colitis18,19.”
§ Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis > Abstract
What the sources say
- Not checked yetcites [18] Kappeler, A. & Mueller, C. Histol. Histopathol. 15, 167–172 (2000).
- Partly supportedcites [19] Nancey, S. et al. Gastroenterology 131, 485–496 (2006). sourceExperimental — accuracy not yet measured
Our copy of Nancey et al. (2006) does draw exactly this kind of parallel: the Discussion states that 'Our finding that CD8+ T cells can initiate colitis is in agreement with several previous observations... showing that intestinal inflammation is consecutive to in vivo priming of CD8+ CTLs reacting to self-modified antigens presented in the gut,' and cites transfer of IFN-gamma-producing, HSP60-specific CD8+ T cells inducing 'autoimmune enteropathy' (ref 36, Steinhoff et al., 'Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells') and a TNF-mediated Crohn's-like disease (ref 37). So the source supports an agreement between its CD8 Tc1/cytotoxic self-reactive immune pattern and reports of autoimmune intestinal pathology. What it does not support is the specificity 'autoimmune colitis': the autoimmune reports it invokes concern small-bowel enteropathy and Crohn's-like (small-intestinal) disease, while the authors' own relapsing colitis is hapten (DNBS)-induced in normal mice, and they explicitly caution that 'the pathogenesis of the mouse and the human diseases may not be similar' (Discussion). (LLM, conf=0.70)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“colonoscopy demonstrated severe colitis that endoscopically resembled ulcerative colitis”
§ Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Numbers of observed OTUs, however, did consistently rise following each FMT in both patients, though in both cases they would later come back down”
§ Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We report the first case series of ICI-associated colitis successfully treated with fecal microbiota transplantation (FMT)”
- Also stated in: § Abstract · plain
“Herein, we document results from the first reported case series of two patients with refractory ICI-associated colitis successfully treated with FMT”
§ Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis > Abstract
plainstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Abstract · plain
17 more claims
Create a free account to see all 47 claims and to verify the 18 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, specific bacteria have been associated with resistance to the development of immune checkpoint inhibitor-associated colitis,197 and fecal microbiota transplants might be used to treat this form of colitis.198”
From Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer (2020) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“Traditional treatment strategies typically involve high-dose corticosteroids and biologics like infliximab or vedolizumab, yet FMT has demonstrated promise for patients who were unresponsive to these interventions.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Wang et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“FMT was first employed as a potential therapeutic option in immuno-oncology practice for refractory ICB–induced colitis, one of the most common irAEs caused by ICB (Marin-Acevedo et al., 2019; Postow et al., 2018; Wang et al., 2018).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Wang et al., 2018
In the citing paper
“The beneficial effect of FMT as a therapeutic modality for immunotherapy-induced toxicity in two patients has been demonstrated by reconstructing the gut microbiome and increasing the proportion of Tregs in the colonic mucosa [132].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [132]
In the citing paper
“FMT might modulate obesity and metabolism in humans and mice 29,30 , ameliorate metabolic syndrome in patients 31 , and contribute to the treatment of refractory immune checkpoint inhibitor (ICI)-associated colitis 32 and recurrent infections by Clostridium difficile 33 .”
From Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice (2019) · cites this paper as [32]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
VSEARCH: a versatile open source tool for metagenomics
(2016) · doi:10.7717/peerj.2584 · Cited by 10,773
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
UniFrac: an effective distance metric for microbial community comparison
Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J., & Knight, R. (2011) · The ISME Journal · doi:10.1038/ismej.2010.133 · Cited by 2,825
Research works printed but not linked: 2
- Kappeler, A. & Mueller, C. Histol. Histopathol. 15, 167–172 (2000).
- Abu-Sbeih, H. et al. J. Immunother. Cancer 6, 1–11 (2018).
Cited by
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
“Fecal microbiota transplantation has also been demonstrated to achieve 75% efficacy in treating 15 refractory colitis cases.(81,82) Preliminary data suggest that GI toxicities are associated with improved survival and treatment outcomes in comparison to other immunotherapy treated patients.”
BackgroundSelf-citationAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationImmune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Metadata
- Authors
- Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., Parra, E. R., Francisco-Cruz, A., Raju, G. S., Stroehlein, J. R., Campbell, M. T., Gao, J., Subudhi, S. K., Maru, D. M., Blando, J. M., Lazar, A. J., Allison, J. P., Sharma, P., Tetzlaff, M. T., Wargo, J. A., & Jenq, R. R.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- Wang, Yinghong
- ORCID
- Wang, Yinghong
- Wiesnoski, Diana H.
- Helmink, Beth A.
- Gopalakrishnan, Vancheswaran
- Jiang, Zhi-Dong
- Abu-Sbeih, Hamzah
- Chang, Chia-Chi
- Parra, Edwin R.
- Raju, Gottumukkala S.
- Campbell, Matthew T.
- Gao, Jianjun
- Subudhi, Sumit K.
- Maru, Dipen M.
- Blando, Jorge M.
- Lazar, Alexander J.
- Allison, James P.
- Sharma, Padmanee
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Jenq, Robert R.
- Venue
- Nature Medicine
- Published
- 2018-11-12
- Volume
- 24
- Issue
- 12
- Pages
- 1804-1808
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6322556
- OpenAlex
- W2898631010
- Cited by
- 740
- References
- 30
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 94 · 2023: 112 · 2022: 110 · 2021: 101 · 2020: 101 · 2019: 73 · 2018: 6
- FWCI
- 26.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-11-27)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Texas MD Anderson Cancer Center
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (R01CA219896, T32CA009599)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, immune checkpoint inhibitors, gut microbiota, regulatory T cells, cancer immunotherapy, refractory colitis
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Ipilimumab, Aged, Colitis, Female, Humans, Immune System, Intestinal Mucosa, Male, Middle Aged, T-Lymphocytes, Regulatory, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. https://app.cochat.ai/papers/10.1038/s41591-018-0238-9
- The paper
- Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., Parra, E. R., Francisco-Cruz, A., Raju, G. S., Stroehlein, J. R., Campbell, M. T., Gao, J., Subudhi, S. K., Maru, D. M., Blando, J. M., . . . Jenq, R. R. (2018). Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. https://doi.org/10.1038/s41591-018-0238-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.